Vitality Biopharma Inc (OTCMKTS:VBIO) Major Shareholder Acquires $2,045,919.46 in Stock

Vitality Biopharma Inc (OTCMKTS:VBIO) major shareholder Joseph E. Loconti bought 4,447,651 shares of the business’s stock in a transaction on Friday, March 29th. The shares were purchased at an average cost of $0.46 per share, with a total value of $2,045,919.46. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Shares of VBIO remained flat at $$0.44 during trading hours on Friday. 24,735 shares of the stock were exchanged, compared to its average volume of 18,016. Vitality Biopharma Inc has a 1-year low of $0.04 and a 1-year high of $2.33.

Vitality Biopharma (OTCMKTS:VBIO) last announced its quarterly earnings data on Thursday, February 14th. The company reported ($0.04) EPS for the quarter. The company had revenue of $0.10 million for the quarter. Vitality Biopharma had a negative net margin of 2,528.42% and a negative return on equity of 119.95%.

COPYRIGHT VIOLATION WARNING: This news story was first reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/04/26/joseph-e-loconti-buys-4447651-shares-of-vitality-biopharma-inc-vbio-stock.html.

About Vitality Biopharma

Vitality Biopharma, Inc engages in the development of cannabinoid pharmaceuticals for the treatment of neurological and inflammatory disorders in the United States. The company's products in pipeline include VBX-100, an oral cannabinoid formulation for inflammatory bowel disease, C.difficile-associated diarrhea and colitis, and narcotic bowel syndrome; and VBX-210, a cannabinoid formulation, which is in preclinical studies for the treatment of gastrointestinal conditions.

Recommended Story: Are Wall Street analysts’ stock ratings worth following?

Receive News & Ratings for Vitality Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitality Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.